Yun Zhong
Stock Analyst at Wedbush
(3.77)
# 718
Out of 5,237 analysts
53
Total ratings
60.87%
Success rate
6.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yun Zhong
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Outperform | $112 → $118 | $99.36 | +18.76% | 4 | May 6, 2026 | |
| PASG Passage Bio | Downgrades: Neutral | $32 → $8 | $4.21 | +90.02% | 4 | Apr 21, 2026 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $273 | $238.66 | +14.39% | 5 | Apr 9, 2026 | |
| RZLT Rezolute | Upgrades: Outperform | $2 → $5 | $3.21 | +55.76% | 3 | Mar 25, 2026 | |
| IRD Opus Genetics | Maintains: Outperform | $8 → $10 | $4.99 | +100.40% | 2 | Mar 12, 2026 | |
| WVE Wave Life Sciences | Maintains: Outperform | $33 → $35 | $7.18 | +387.47% | 4 | Mar 6, 2026 | |
| MNKD MannKind | Maintains: Outperform | $10 → $8 | $3.52 | +127.27% | 1 | Mar 5, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $32 → $34 | $19.96 | +70.38% | 13 | Jan 23, 2026 | |
| KROS Keros Therapeutics | Maintains: Neutral | $15 → $16 | $12.07 | +32.56% | 3 | Nov 6, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Outperform | $80 → $18 | $17.06 | +5.51% | 2 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $7.71 | +263.16% | 1 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $4.05 | +97.53% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.46 | +79.37% | 1 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 | $3.63 | +781.54% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $28 | $3.22 | +769.57% | 2 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.81 | - | 2 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $46 | $27.66 | +66.31% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.25 | +3,906.41% | 1 | May 5, 2021 |
Protagonist Therapeutics
May 6, 2026
Maintains: Outperform
Price Target: $112 → $118
Current: $99.36
Upside: +18.76%
Passage Bio
Apr 21, 2026
Downgrades: Neutral
Price Target: $32 → $8
Current: $4.21
Upside: +90.02%
Ascendis Pharma
Apr 9, 2026
Reiterates: Outperform
Price Target: $273
Current: $238.66
Upside: +14.39%
Rezolute
Mar 25, 2026
Upgrades: Outperform
Price Target: $2 → $5
Current: $3.21
Upside: +55.76%
Opus Genetics
Mar 12, 2026
Maintains: Outperform
Price Target: $8 → $10
Current: $4.99
Upside: +100.40%
Wave Life Sciences
Mar 6, 2026
Maintains: Outperform
Price Target: $33 → $35
Current: $7.18
Upside: +387.47%
MannKind
Mar 5, 2026
Maintains: Outperform
Price Target: $10 → $8
Current: $3.52
Upside: +127.27%
Sarepta Therapeutics
Jan 23, 2026
Maintains: Outperform
Price Target: $32 → $34
Current: $19.96
Upside: +70.38%
Keros Therapeutics
Nov 6, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $12.07
Upside: +32.56%
MoonLake Immunotherapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $80 → $18
Current: $17.06
Upside: +5.51%
Aug 11, 2025
Initiates: Outperform
Price Target: $28
Current: $7.71
Upside: +263.16%
Aug 7, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $4.05
Upside: +97.53%
May 27, 2025
Initiates: Outperform
Price Target: $8
Current: $4.46
Upside: +79.37%
May 16, 2025
Reiterates: Outperform
Price Target: $32
Current: $3.63
Upside: +781.54%
Feb 9, 2023
Maintains: Buy
Price Target: $35 → $28
Current: $3.22
Upside: +769.57%
Feb 2, 2023
Downgrades: Neutral
Price Target: n/a
Current: $6.81
Upside: -
Jun 15, 2021
Initiates: Buy
Price Target: $46
Current: $27.66
Upside: +66.31%
May 5, 2021
Initiates: Buy
Price Target: $10
Current: $0.25
Upside: +3,906.41%